Cellares Expands Automation Platforms to Gene-Edited Stem Cell Therapies
Event summary
- Cellares collaborates with Stanford CDCM and IMA to automate manufacturing for gene-edited hematopoietic stem cell (HSC) therapies.
- The partnership aims to standardize platform manufacturing on Cell Shuttle™ and release assays on Cell Q™ for multiple indications.
- Automation efforts are already underway with the HARBOR KNOCK gene-editing approach, targeting HIV and rare inherited diseases.
The big picture
Cellares' expansion into gene-edited stem cell therapies marks a strategic shift from T-cell therapies, addressing a growing need for scalable and cost-effective manufacturing solutions. This collaboration with Stanford aligns with broader industry trends toward automation in cell therapy production, aiming to reduce variability and enhance accessibility for patients with limited treatment options.
What we're watching
- Technology Scalability
- How Cellares' automation platforms will scale to support multiple rare disease programs and improve patient access.
- Market Expansion
- Whether the collaboration with Stanford can position Cellares as a leader in gene-edited HSC therapy manufacturing.
- Regulatory Approvals
- The pace at which automated manufacturing processes for gene-edited therapies gain regulatory approvals.
Related topics